Clinical Trials Directory

Trials / Unknown

UnknownNCT01295801

Vitamin B6 on Relieving Linezolid-associated Cytopenias

The Effects and Mechanism of Vitamin B6 on Relieving Linezolid-associated Cytopenias

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Chinese PLA General Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Linezolid is the first approved synthetic oxazolidinone that is active against multidrug-resistant Gram-positive pathogens. Because of its significant efficacy, linezolid is widely used in clinical treatment. However, the side effects of linezolid commonly lead to anemia and thrombocytopenia. This hematological toxic effects limit its prolonged used. The investigators have found that Vitamin B6 application, as a preventive, auxiliary therapy, can relieve anemia and thrombocytopenia. The present study was designed to verify the effects of Vitamin B6 in the prevention of linezolid-associated cytopenias and investigate its mechanism.

Detailed description

Infected patients receiving linezolid therapy are divided into two groups, i.e. the linezolid group and the linezolid + vitamin B6 group, the line of division being whether vitamin B6 is to be applied or not in the course of treatment. The purpose is to evaluate the role that vitamin B6 plays, during the process of linezolid therapy, in the relief of erythropenia and cytopenias.

Conditions

Timeline

Start date
2010-11-01
Primary completion
2011-07-01
Completion
2011-09-01
First posted
2011-02-15
Last updated
2011-02-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01295801. Inclusion in this directory is not an endorsement.